Randomized Trial Comparing Colesevelam vs. Ezetimibe
- Registration Number
- NCT02682680
- Lead Sponsor
- LMC Diabetes & Endocrinology Ltd.
- Brief Summary
A 24-week, randomized, open-label study investigating the efficacy, safety and tolerability of colesevelam 3.75 g daily compared to ezetimibe 10 mg daily, as an add-on to baseline statin therapy in patients with type 2 diabetes mellitus (T2DM) who are not at target for glycated hemoglobin (HbA1c) (\> 7.0%) and low-density lipoprotein (LDL) cholesterol (\> 2.0 mmol/L).
- Detailed Description
This study will enroll 200 adult patients with T2DM who are not at target for HbA1c and LDL cholesterol. Patients who are on baseline statin therapy will be randomly assigned in a 1:1 ratio to colesevelam 3.75 g daily for 24 weeks, or ezetimibe 10 mg daily for 24 weeks. If a patient has statin intolerance, they may be on a fibrate and/or niacin, or on no lipid lowering therapy. The primary efficacy objectives are
1. to demonstrate that colesevelam 3.75 g daily is non-inferior to ezetimibe 10 mg daily as add-on to statin therapy for patients achieving a composite target of HbA1c (≤ 7.0%) and LDL cholesterol (≤ 2.0 mmol/L) at week 24, and
2. to compare the proportion of patients achieving a composite target of HbA1c (≤ 7.0%) and LDL cholesterol (≤ 2.0 mmol/L) at week 24.
This study will also assess the primary composite outcome in a sub-group of patients on sodium/glucose cotransporter 2 inhibitor (SGLT2i) therapy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
- Diagnosis of type 2 diabetes > 6 months
- HbA1c level between 7.1 to 10.0% (inclusive) within three months of study enrollment
- LDL cholesterol > 2.0 mmol/L within three months of study enrollment
- Receiving a stable dose of statin for a minimum of three months, which the investigator does not plan to change over the 24-week trial period. If patient has documented statin intolerance, may be on a fibrate and/or niacin, or on no lipid lowering therapy
- Stable diabetes medications for previous three months (apart from adjustment of insulin dose)
- Informed consent
- Use of a second lipid lowering therapy other than statin within three months of study enrolment, unless on a fibrate and/or niacin if patient has statin intolerance
- Triglycerides ≥ 5.0 mmol/L or incalculable LDL cholesterol
- Significant liver enzyme or CK elevation defined as CK or ALT ≥ 3x upper limit of normal (ULN)
- Pregnant or breast feeding or planning to become pregnant or breast feed during the study 6) Chronic kidney disease (CKD) stage ≥4 or estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m-squared 7) Severe gastroparesis or history of significant bowel resection 8) Current use of any Investigational Product
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Colesevelam Colesevelam Colesevelam 3.75 g daily (tablets or oral suspension) for 24 weeks Ezetimibe Ezetimibe Ezetimibe 10 mg once daily for 24 weeks
- Primary Outcome Measures
Name Time Method Proportion of subjects who achieve target HbA1c and LDL cholesterol 24 weeks target HbA1c: ≤ 7.0%; target LDL cholesterol: ≤ 2.0 mmol/L
- Secondary Outcome Measures
Name Time Method Proportion of subjects who achieve the primary outcome measure in the sub-group of subjects on sodium/glucose cotransporter 2 inhibitor (SGLT2i) therapy 24 weeks Absolute change in LDL cholesterol 24 weeks Proportion of subjects achieving a composite target of glycemic control, LDL cholesterol control and blood pressure control 24 weeks glycemic control: A1c ≤ 7.0%; LDL cholesterol control: ≤ 2.0 mmol/L; blood pressure control: ≤ 130/80 mm Hg
Proportion of subjects with ≥ 0.3% reduction in HbA1c and ≥ 10% reduction in LDL cholesterol from baseline 24 weeks Absolute change in high-sensitivity C-reactive protein (hs-CRP) levels from baseline 24 weeks Absolute change in non-HDL cholesterol in sub-group of subjects on SGLT2i therapy 24 weeks Absolute change in FPG in sub-group of subjects on SGLT2i therapy 12 weeks and 24 weeks Proportion of subjects achieving a composite target of glycemic control with no hypoglycemia and no weight gain 24 weeks Proportion of subjects with ≥ 0.5% reduction in HbA1c and ≥ 15% reduction in LDL cholesterol 24 weeks Absolute change in triglyceride levels from baseline 24 weeks Proportion of subjects achieving target HbA1c and LDL cholesterol in the sub-group of subjects on non-insulin therapies 24 weeks Rate of non-severe and severe hypoglycemia 24 weeks Severe hypoglycemia is defined as hypoglycemia requiring third party intervention of another person to actively administer carbohydrate, glucagon or other resuscitative actions.
Absolute change in HbA1c 24 weeks Absolute change in LDL cholesterol in sub-group of subjects on SGLT2i therapy 24 weeks Absolute change in HbA1c in sub-group of subjects on SGLT2i therapy 12 weeks and 24 weeks Absolute change in FPG in the sub-group of subjects on non-insulin therapies 24 weeks Absolute change in non-HDL cholesterol in the sub-group of subjects on non-insulin therapies 24 weeks Absolute change in alanine aminotransferase (ALT) 24 weeks Absolute change in creatine kinase (CK) 24 weeks Absolute change in non-high-density lipoprotein (non-HDL) cholesterol 24 weeks Absolute change in fasting plasma glucose (FPG) 24 weeks Absolute change in HbA1c in the sub-group of subjects on non-insulin therapies 24 weeks Absolute change in LDL cholesterol in the sub-group of subjects on non-insulin therapies 24 weeks
Trial Locations
- Locations (9)
LMC Barrie
🇨🇦Barrie, Ontario, Canada
LMC Brampton
🇨🇦Brampton, Ontario, Canada
LMC Calgary
🇨🇦Calgary, Alberta, Canada
LMC Etobicoke
🇨🇦Etobicoke, Ontario, Canada
Manna Toronto
🇨🇦Toronto, Ontario, Canada
LMC Bayview
🇨🇦Toronto, Ontario, Canada
LMC Markham
🇨🇦Markham, Ontario, Canada
LMC Oakville
🇨🇦Oakville, Ontario, Canada
LMC Thornhill
🇨🇦Thornhill, Ontario, Canada